News
News Center
2018-09-15
Source: Stem Cell Home On September 14, 2018, Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd. (referred to as Jiuzhitang Maker), established by Jiuzhitang, a traditional Chinese medicine pharmaceutical company, signed an investment agreement with U.S.-based Stemedica Cell Technologies, Inc., a California-based biopharmaceutical company located in San Diego’s Biotech Valley and boasting over a decade of experience in stem cell research, development, manufacturing, and marketing. Under the terms of the agreement, Jiuzhitang Maker will introduce cutting-edge stem cell production technologies and a state-of-the-art preparation platform from one of the world’s leading stem cell companies. Over the next 3 to 5 years, the company plans to build a commercial-grade stem cell production facility meeting both U.S. and EU cGMP standards at the Beijing Daxing Biomedical Industry Base. This strategic move marks Jiuzhitang, a century-old Chinese medicine enterprise, officially entering the rapidly growing fields of stem cell drug research, clinical applications, and industrialization—signaling that China’s era of stem cell-based pharmaceuticals is on the horizon.
+
2018-09-15
Source: Physician News On September 14, 2018, the "Global Stem Cell Industry Development Summit Forum" was held in Beijing. As a key focus of future medical research, stem cell technology has been continuously included in multiple national and regional science and technology development plans and specialized guidelines over the years.
+
2018-09-15
Source: Securities Times (Reporter Wang Xiaowei) Jiuzhitang has launched the Jiuzhitang Yonghe Qihang Fund, which on the 14th signed an investment agreement with Stemedica Cell Technology Co., Ltd., based in San Diego, the "Biotech Valley" of the U.S. According to the agreement, Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd. (hereinafter referred to as Jiuzhitang Maker) will introduce cutting-edge stem cell production technologies and a state-of-the-art preparation platform from a globally leading stem cell company. Over the next 3 to 5 years, Jiuzhitang Maker plans to establish a commercial-grade stem cell production facility meeting both U.S. and EU cGMP standards at the Daxing Biomedical Industry Base in Beijing. This move marks Jiuzhitang, a time-honored Chinese medicine enterprise with over a century of history, officially entering the rapidly growing stem cell industry.
+
2018-09-15
Multiple major companies enter the market, accelerating the launch of China's stem-cell drugs.
Source: Science and Technology Daily Another major development has emerged in China's stem cell therapy field. On September 14, traditional Chinese medicine pharmaceutical company Jiuzhi Tang announced that Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd. (hereafter referred to as Jiuzhitang Maker) will partner with U.S.-based Stemedica Cell Technology Co., Ltd., a company with over a decade of experience in stem cell R&D and manufacturing. Together, they plan to build a commercial-grade stem cell production facility meeting both U.S. and EU cGMP standards within the next 3 to 5 years. This strategic move marks Jiuzhi Tang's official entry into the stem cell industry. "Our goal is to develop stem cell-based therapeutic drugs," Jiuzhitang Maker CEO Gao Yansong told a reporter from Science and Technology Daily.
+
2018-09-14
Source: BioValley On September 14, 2018, Jiuzhitang Maker Cell Technology Co., Ltd. (hereafter referred to as Jiuzhitang Maker), established by the traditional Chinese medicine pharmaceutical company Jiuzhitang, signed an investment agreement with U.S.-based Stemedica Cell Technologies, Inc. (referred to as U.S. Stemedica), a biopharmaceutical company based in San Diego's Biotech Valley and boasting over a decade of experience in stem cell research, development, manufacturing, and marketing. According to the agreement, Jiuzhitang Maker will introduce cutting-edge stem cell production technologies and a state-of-the-art preparation platform from one of the world’s leading stem cell companies, aiming to establish operations within three to five years at the Beijing Daxing Biomedical Industry Base.
+
Here is the title—h1 placeholder text
Copyright © Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd.
Powered by: 300.cn SEO | Privacy Policy